Current standard chemotherapy for GBM primarily relies on temozolomide (TMZ) in combination with radiotherapy, yet its efficacy is often limited by the development of resistance mechanisms, such as MGMT promoter methylation status and DNA repair pathway activation [42]. Here, MGMT is linked to glioblastoma.